A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer

Bell, 2005, Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials, JCO, 23, 8081, 10.1200/JCO.2005.02.7078 Ladanyi, 2008, Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond, Mod Pathol, 21, S16, 10.1038/modpathol.3801018 Herbst, 2008, Lung cancer, N Engl J Med, 359, 1367, 10.1056/NEJMra0802714 Esposito, 2010, Lung cancer: are we up to the challenge?, Curr Genomics, 11, 513, 10.2174/138920210793175903 Ohashi, 2013, Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease, JCO, 31, 1070, 10.1200/JCO.2012.43.3912 Soria, 2018, Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer, N Engl J Med, 378, 113, 10.1056/NEJMoa1713137 Murakami, 2018, Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations, Cancer Sci, 109, 2852, 10.1111/cas.13724 Azuma, 2018, ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor-naive Japanese patients with EGFR mutation-positive non-small-cell lung cancer, Cancer Sci, 109, 2532, 10.1111/cas.13651 Yu, 2017, A phase I, dose escalation study of oral ASP8273 in patients with non-small cell lung cancers with epidermal growth factor receptor mutations, Clin Cancer Res, 23, 7467, 10.1158/1078-0432.CCR-17-1447 Califano, 2015, Expert consensus on the management of adverse events from EGFR tyrosine kinase inhibitors in the UK, Drugs, 75, 1335, 10.1007/s40265-015-0434-6 Tan, 2017, Tyrosine kinase inhibitors show different anti-brain metastases efficacy in NSCLC: a direct comparative analysis of icotinib, gefitinib, and erlotinib in a nude mouse model, Oncotarget, 8, 98771, 10.18632/oncotarget.21936 Cross, 2014, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer, Cancer Discov, 4, 1046, 10.1158/2159-8290.CD-14-0337 Walter, 2013, Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC, Cancer Discov, 3, 1404, 10.1158/2159-8290.CD-13-0314 Khozin, 2014, U.S. Food and Drug Administration approval summary: erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations, Oncologist, 19, 774, 10.1634/theoncologist.2014-0089 Douillard, 2014, First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study, Br J Cancer, 110, 55, 10.1038/bjc.2013.721 Iressa (Gefitinib) [Prescribing Information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP 2018. Terceva (Erlotinib) [Prescribing Information]. Northbrook, IL: Astellas Pharma US, Inc. 2016.